drugset / Trial / NCT03168464
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Phase 1/2
Terminated
15 enrolled
Weill Medical College of Cornell University
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
NSCLC patients with metastatic disease who have failed at least one prior treatment and have a minimum of two metastatic lesions (at least one measurable), are eligible if they have an ECOG Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks) concurrently with radiation (6Gy x 5 fractions). Nivolumab (every 2 weeks) will be given in addition to ipilimumab on day 22.
Timeline
- Start
- 2017-10-09
- Primary completion
- 2022-03-11
- Completion
- 2022-03-11
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |